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Abstract 
Background. Lung cancer screening with annual low-dose computed tomography is relatively new for 
long-term smokers in the United States supported by a United States Preventive Services Task Force 
Grade B recommendation. As screening programs are more widely implemented nationally and providers 
engage patients about lung cancer screening, it is critical to understand behavior among high-risk 
smokers who opt out to improve shared decision-making processes for lung cancer screening. 
Objective. The purpose of this study was to explore the reasons for screening-eligible patients’ decisions 
to opt out of screening after receiving a provider recommendation.  
Methods. Semi-structured qualitative telephone interviews were performed with 18 participants who met 
lung cancer screening criteria for age, smoking and pack-year history in Washington State from 
November 2015 to January 2016. Two researchers with cancer screening and qualitative methodology 
expertise conducted data analysis using thematic content analytic procedures from audio-recorded 
interviews.  
Results. Five primary themes emerged for reasons of opting out of lung cancer screening: 1) Knowledge 
Avoidance; 2) Perceived Low Value; 3) False Positive Worry; 4) Practical Barriers; and 5) Patient 
Misunderstanding.  
Conclusion. The participants in our study provided insights into why some patients make the decision to 
opt out of low-dose computed tomography screening, which provides knowledge that can inform 
intervention development to enhance shared decision-making processes between long-term smokers and 
their providers and decrease decisional conflict about screening. 
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Introduction 
Lung cancer screening with low-dose computed tomography (LDCT) has become increasingly 
available in the US since its grade B recommendation from the US Preventive Services Task Force 
(USPSTF) in 2013 for long-term smokers.1 Healthcare systems have been rapidly rolling out screening 
programs.2 For the first time, shared decision-making has been tied to cancer screening through 
reimbursement mandate of documentation of a shared decision-making and counseling visit for 
reimbursement of lung cancer screening.3 This Medicare coverage requirement is due to be implemented 
in January 2017.2,3 Shared decision-making is conceptualized as a process in which a healthcare provider 
offers information about a treatment or healthcare option to an individual, discussing the benefits and 
potential harms as well as uncertainties, and engaging the patient to weigh their values and preferences 
to arrive at a decision collaboratively.4 
For eligible patients, the decision to participate in screening may not be straightforward. Lung 
cancer screening is new, and many individuals are unaware of the test and its balance of benefits and 
risks. While the primary benefit of lung cancer screening is the potential to find lung cancer at an earlier 
stage where more treatment options exist, the risks associated with lung cancer screening include the 
potential for overdiagnosis, cumulative radiation exposure with a yearly commitment to screen with LDCT, 
and false positive findings. An indeterminate finding such as a lung nodule can lead to subsequent 
invasive follow-up procedures including a biopsy.5,6 Furthermore, lung cancer screening targets long-term 
smokers. Unlike the relatively healthy populations targeted for breast and colorectal cancer screening, 
this population is unique, different and has a high potential for smoking-related comorbidities. Of equal 
importance, smokers experience stigma, perceive blame, and battle nicotine addiction. Perceived self-
infliction secondary to the choice to smoke presents a layer of complexity not present in other types of 
cancer screening. Based on previous qualitative work, stigma and medical mistrust seem to be uniquely 
relevant in lung cancer screening.7 Because stigma and medical mistrust may influence the decision not 
to screen for lung cancer, understanding the decision-making process among patients who opt out is 
critical. This knowledge is a foundational component of understanding the patient perspective, and can 
inform effective intervention development to enhance the shared decision-making process. The purpose 
of this study was to explore the patient decision to opt out of screening after receiving a provider 
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recommendation for lung cancer screening. There is a dearth of literature on the patient perspective of 
lung cancer screening,7-9 and to our knowledge, no one has explored the patient decision to opt out of 
screening after having a discussion about screening with a provider and receiving a recommendation. 
Findings from this study extend the work done by others exploring the decision to screen by offering 
insight into the decision not to screen,9-11 which can inform interventions that target both the patient and 
provider to enhance the shared decision-making process in lung cancer screening decisions. 
Methods 
Design Overview and Setting 
We conducted a qualitative study to explore descriptions of life events shared by people with a 
common concern;12 in this case, the decision to screen for lung cancer. In 2015, Group Health 
Cooperative (GHC), a mixed-model delivery system in Washington state, had a soft launch of a 
population-based lung cancer screening program, set within primary care clinics. Information regarding 
the new screening guideline was actively disseminated to providers and a registry for providers to 
document lung cancer screening discussions employed. The soft launch did not involve active outreach to 
screening-eligible patients meaning patients who met screening guidelines did not receive promotional 
materials outside of a clinic visit about lung cancer screening. Patients were identified in the context of a 
healthcare appointment with their primary care provider in which a discussion about lung cancer 
screening occurred. For providers, the screening guideline was deployed through lunch-time continuing 
medical education and direct communication through electronic clinical pearls and a toolkit within the 
electronic health record system to support documentation of a patient discussion and the patient’s 
decision about screening. At the initial program launch, there were no formal shared decision-making 
tools provided, but soft decision aides for provider use and an After Visit Summary were available. These 
did not meet formal decision aid criteria.13 GHC has since updated their decision-making tools to exceed 
those criteria. 
Medical assistants updated smoking history and pack-year information when patients arrived for a 
healthcare visit to identify potentially eligible patients for the healthcare provider. The electronic health 
record was modified with a module designed and developed within GHC to systematically capture 
information about individuals approached for lung cancer screening including eligibility and 
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documentation about the patient’s decision whether or not to screen. In addition to knowing if screening 
was discussed, we were able to identify individuals who opted out of screening. 
Recruitment of Participants 
We recruited 18 participants aged 55 to 77 years using a purposive sampling strategy from GHC 
between November 2015 and January 2016 who met the following inclusion criteria: (1) eligible for and 
offered lung cancer screening by their primary care provider in the past four months prior to recruitment; 
(2) did not have lung cancer screening despite being offered referral; (3) able to speak and understand 
English; and (4) able to participate in a telephone interview. Individuals eligible for lung cancer screening 
according to the USPSTF guideline are aged 55 to 77 years old, current or former smokers who have quit 
within the past 15 years, and have 30 pack-year tobacco smoking history. 
We used electronic health records to identify potential participants to whom recruitment letters, 
signed by the co-principal investigators, were sent. The recruitment letter introduced the study 
opportunity, indicated they would be called by study staff, and offered the research office’s telephone 
number to call and leave a message to opt out of being contacted. One week after recruitment letters 
were mailed, study staff followed up by telephone with individuals who did not call to refuse participation. 
Ninety-four recruitment letters were mailed; four individuals called and left a message to opt out of further 
contact about the study. Seventy-four participants were reached by telephone. All were screened for 
eligibility before being offered participation in the study. Of the 74 reached and screened, 36 were eligible, 
17 declined to participate in the study, and 19 participated (52.8%). Sociodemographic variables did not 
differ between those who did and those who did not agree to participate. Once an individual was 
determined to be eligible and willing, the informed consent process was performed.  Most interviews took 
place during the same outreach call. However, some interviews were scheduled at a later time that was 
more convenient for the participant. Participant recruitment ended when sufficient information had been 
obtained to identify several distinct themes and saturation was reached.14 A $50 check was provided after 
completion of the interview for their time.  
Data Collection 
We developed an interview guide that focused on: (1) details about the lung cancer screening 
conversation with the provider and perceptions of the patient-provider discussion about screening; and (2) 
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reasons for opting out of lung cancer screening including specific factors influencing the patients’ 
decision. A trained research specialist conducted individual telephone interviews using this semi-
structured interview guide (Table 1). Interviews were digitally audiotaped, transcribed verbatim and de-
identified by a secure transcription service. Participants were also invited to ask questions and provide 
additional details/feedback. Interviews ranged from 36 to 68 minutes in duration. Data collection ended 
after 18 interviews because, although the details and examples were often unique, saturation was 
reached in which information to identify distinct themes relevant to the decision to opt out of lung cancer 
screening was obtained. 
Data Analysis 
Data were analyzed using standard content analytic procedures.15 Two researchers with 
expertise in cancer screening and qualitative methods (LCH and SDB) conducted data analysis by 
independently reading all transcripts. A coding scheme was developed, with input from the research team 
comprised of researchers with expertise in lung cancer screening behavior, cancer epidemiology, and 
health services research. Each transcript was independently coded by providing labels for each relevant 
text unit, which is any word, phrase, sentence, or story that provided information to address the study 
purpose. An approach using inductive analysis was used to derive themes from the iterative review and 
interpretation of the data.16 A coding matrix was created using a Microsoft Word table format to display 
the relevant, identified text units. Text units were then compared, contrasted and independently grouped 
into sub-categories. The researchers then met to discuss themes that emerged from individual coding 
and compare the degree of congruence between coding, themes, and classifications. Discrepancies were 
discussed and reconciled by consensus. 
Ethical Considerations 
 The study was approved by the Group Health Research Institute’s Human Subjects Research 
Committee for all study activities prior to the initiation of recruitment. Participants provided verbal consent 
prior to data collection. Confidentiality was assured by de-identification of transcripts using identification 
codes. 
Results 
  
7 
7 
The median (IQR) participant age was 68 (57, 74) years. Most were Caucasian (89%), female 
(61%), and current smokers (61%). See Table 2. Participants recruited into and completing the study 
represented healthcare encounters of 10 unique primary care providers. Results are organized according 
to two main topics: (1) patient-provider discussion about lung cancer screening; and (2) reasons for 
opting out of lung cancer screening. Table 3 summarizes themes and subthemes of the findings. 
Patient-Provider Discussion About Lung Cancer Screening 
All participants reported the provider initiated the discussion about lung cancer screening 
opportunistically, meaning that the patients were having either general wellness visits (11 visits) or were 
being seen for a particular condition or symptom (6 visits). The majority had never heard of lung cancer 
screening before this discussion, and most described the discussion as short or limited, regardless of 
type of visit. Participants reported screening being brought up in the context of their smoking history, 
either because they were current smokers or had been a long-term smoker. Illustrative comments include: 
“We talked about cigarette smoking [as] something that I knew was going to greatly impact diabetes, but 
at that point my plate was really full, and we could go into the smoking at a later date…he suggested at 
that point that maybe I should get the lung screening while I was getting everything else tested.” (F, age 
66); “He told me that I would be a very good candidate for it and that he recommends it highly.” (M, age 
70); and “She said very specifically because I’d smoked more than 15 years…she said it was a particular 
x-ray for smokers.” (F, age 69) 
Participants consistently described brief discussions presenting the option of lung cancer 
screening but, from their perspective, lacked description or engagement in a shared discussion about 
screening beyond eligibility. Two themes emerged: (1) Being Qualified to Screen; and (2) Discussion 
Followed by Provider Recommendation. 
Being Qualified to Screen was characterized by a brief presentation of lung cancer screening as 
an option that primarily centered on screening qualification secondary to smoking history followed by 
printed materials to take home. Screening was presented as an option and not typically accompanied by 
a specific recommendation. Many participants noted the discussion was quite brief and a small 
component of the visit. Most information was gleaned from the educational printed materials provided and 
not the patient-provider discussion. These types of experiences are illustrated in the following quotes: 
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“She [provider] handed me a paper and she said ‘read over this’…she didn’t really [describe it]. I got most 
of my information off the paper. I mean, she said I didn’t have to do it, but if I’d like to, they could set it up 
and I could go on and have it done.” (F, age 63); “She [provider] had just brought it up and said ‘oh, 
here’s some paperwork and if you want to do this, you can.” (F, age 69); and “She gave me a printout and 
I brought that home and read it, mostly. That’s where I got most of the information”. (F, age 67) 
Discussion Followed by Provider Recommendation was characterized by a short provider-
initiated and led discussion followed by a screening recommendation. For example, one participant noted, 
“I know she said that she wanted me to have it done, because I’d smoked before, and at my age it should 
be done”, and another describing, “he recommended it because I had smoked a certain amount of time, a 
certain amount of cigarettes per day and…was eligible”. (M, age 72) 
Reasons for Opting Out of Lung Cancer Screening 
When asked about the decision to opt out of lung cancer screening, the majority indicated they 
did not opt out initially during the clinical encounter, but rather their decision to opt out was made after 
they left the office. Five primary themes emerged: (1) Knowledge Avoidance; (2) Perceived Low Value; 
(3) False Positive Worry; (4) Practical Barriers; and (5) Patient Misunderstanding. All five themes are 
reflective of barriers, which is theoretically consistent with the Health Belief Model.17 
Knowledge Avoidance primarily manifested as fear of finding lung cancer and what that would 
mean for the individual. Subthemes reflective of Knowledge Avoidance included: (1) Fear of the Disease; 
and (2) Fear of the Treatment. A male participant described, “I’m 61 years old. I mean, you know, if I have 
lung cancer…basically I just don’t want to know about it”, highlighting his fear of the disease. Similarly, a 
66-year-old woman stated, “so I didn’t choose to go do the test. If I did try to go do the test, I would be 
kind of scared, because I’ve been smoking since I was 12 and I really don’t – I mean, I can imagine what 
my lungs look like and what they might find.” Whereas a 59-year-old woman recounted her decision to opt 
out of lung cancer screening by noting, “I think it’s fear of the unknown – if I know, well then there’s a 
scary response. You know you have to follow through and do more and more.” 
Perceived Low Value was characterized as feeling the screening test is of little to no benefit. 
Subthemes reflective of Perceived Low Value included: (1) Wasted Effort; and (2) Skepticism. There was 
a disconnect between the benefit of potentially finding lung cancer early and what could be done if lung 
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cancer was detected. Reflective of the subtheme, Wasted Effort, a 61-year-old man noted, “It could show 
me if I had lung cancer and – what are they going to do?...screening for it doesn’t really make any 
difference because I’ll either come down with lung cancer or I won’t”. Skepticism was also voiced about 
the benefit of a negative screening result. For example, a 63-year-old woman adamantly noted, “What is it 
going to do? What is it going to prove? That I don’t have it right now. But in five years I could end up 
developing lung cancer from my past exposure”. 
False Positive Worry was a concern raised by five participants. They indicated they were heavily 
influenced not to screen after reading the take-home materials that described the likelihood of a false 
positive result that could lead to invasive procedures. Having a false positive would induce too much 
stress and anxiety and caused them to distrust the tests’ value. Illustrative comments include: a 66-year-
old female noting, “It was saying ‘risks of screening, false positive test results’…I had just gotten an 
abnormal mammogram reading…and I’m sitting here looking at a 95% chance that I’m going to be 
misdiagnosed, and I have to go through it all again. Only this time the tests involved are more invasive. 
That didn’t exactly excite me…I just was not ready to put myself through that kind of stress.” Similarly, 
another participant recalled, “I did schedule one and then after I read the print out and the office called 
me, I canceled it…the false positives were so high. I thought why – I wanted to think about it some more, 
because I thought that would be so stressful to think that you had it, and really you didn’t. I mean it was 
like 90-some percent, I believe.” (F, age 67) 
Practical Barriers represented time and logistical issues. Some opted out because of the 
inconvenience associated with the screening location and time it would take to travel to and from the 
facility to have the scan. For example, one participant noted, “She [provider] had it all set up – I just had 
to give them a day I’d come in and see them, but I was still working at that time and I really didn’t have 
time to get over there during the week and so I haven’t had it done”. (M, age 68) 
Finally, a theme characterized by Patient Misunderstanding emerged as well. Even though lung 
cancer screening is a covered preventive service with a zero-dollar copay under the Affordable Care Act,3 
some misunderstood associated screening costs as noted by a 65-year-old woman noting lung cancer 
screening was “just very, very expensive…it was like $500. I gathered that was per year. It just seemed 
more than I wanted to spend.”; and another participant stating, “once we got to the point where I realized 
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it wasn’t going to be covered by my insurance, that was basically the end of it…if it had been less 
expensive, I would have done it”. (M, age 67) Ultimately, these participants made the decision to opt out 
of lung cancer screening secondary to misunderstanding associated out-of-pocket cost. 
Discussion 
To our knowledge, this is the first study to explore the decision to opt out of lung cancer screening 
in screening eligible patients. Reasons individuals identified for opting out of screening were reflective of 
barriers consistent with the Health Belief Model.17 As established in breast and colorectal cancer 
screening,18, 19 and early qualitative research in lung cancer screening,7, 9, 20-22 fear of finding and being 
diagnosed with cancer is a compelling reason to decline to screen. Feeling screening tests are a waste of 
time or unnecessary, as well as practical reasons such as time, inconvenience, and cost are consistent 
with reasons given by individuals who opt out of other types of cancer screening.18,19 Based on the 
educational materials, many participants expressed concern about the high number of false positive 
findings and the worry that would induce along with the potential for subsequent invasive diagnostic 
procedures. Unlike other types of cancer screening, this highlights potential messaging and presentation 
differences in lung cancer screening patient educational materials versus other types of cancer screening 
worthy of further exploration. Additionally, many patients reported the lung cancer screening topic as a 
small component of their healthcare encounter and being provided post-visit educational materials to 
review leaving the patient to process themselves. 
Knowledge regarding lung cancer screening overall as well as benefits and potential harms 
remains low in the general US population.7,9 When a patient comes in for a clinical visit having never 
heard of lung cancer screening, the expectation of making an informed decision is a challenge. For those 
in this study, because most were unaware of lung cancer screening, screening being described and 
offered in the context of a brief discussion or via pamphlet did not foster engagement to fully consider the 
benefits versus risks nor result in an informed decision. Further, for those patients in the study that 
described receiving patient education material and making the decision to not screen for lung cancer 
based upon the high false positive rate associated with screening, this highlights the complexity of 
educating patients about cancer screening in general. A false positive rate is the rate of positive results 
that are identified and subsequently determined to be benign representing the sensitivity of the test 
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versus the specificity.23 While it is accurate to present a 95% false positive rate in lung cancer screening 
and a recommended talking point for providers in patient education regarding screening driven by the 
USPSTF lung cancer screening guidelines,3 it is understandable that patients struggle to interpret this 
information accurately. This highlights the complexity of presenting lung cancer screening to a patient 
outside of a clinical encounter reflective of shared decision-making or through a pamphlet and expecting 
the patient to make a high-quality, informed decision. Shared decision-making is a process that may 
necessitate more than one clinical encounter and/or pre- and post-visit support to foster an informed, 
values-based decision. Tailored lung cancer screening materials sent to an eligible patient pre-visit may 
help prime the patient for the shared decision-making process about screening allotting more time for 
providers to focus on educating patients about their personal risk and complex concepts related to cancer 
screening such as false positive results and potential for over-diagnosis. Furthermore, the post-visit time 
period is ideal for continued educational support for those who are undecided after engaging in a patient-
provider discussion about lung cancer screening.24-26 It is important, however, to remember that within the 
context of opportunistic screening discussions, there might not be sufficient time to fully discuss all 
screening-related questions as well as the actual intent of the visit. Therefore, it is essential for practices 
to consider how to share material with patients pre- and post-visit to address time constraints while 
engaging and empowering patients in the decision-making process. 
Our findings provide an initial glimpse into the decision-making process about lung cancer 
screening early in its implementation post-USPSTF recommendation. The timeline for guideline diffusion 
into practice for both patients and providers is critical as we assess lung cancer screening implementation 
over time. With the reimbursement requirement of shared decision-making,2 we have a unique opportunity 
to design healthcare encounters that promote an informed, values-based decision around screening. 
Patients who are involved in decision-making about their health report increased decision quality.27 
Specifically, decision quality can be improved through: 1) increased knowledge; 2) supporting a patient’s 
values; 3) increasing patient-provider communication, including the provision of information people 
understand consistent with educational level; 4) helping patients who are undecided make a decision that 
is right for them; 5) decreasing decisional conflict through meaningful shared decision-making 
interactions; and 6) decreasing passive participation in the decision-making process.28, 29 
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Limitations and Strengths 
The results of this study should be interpreted in the context of its limitations and strengths. While 
a key ingredient in qualitative research is development of rapport during interviews, performing a 
telephone interview to collect data may influence rapport, which may limit the depth of the interview and 
impact the findings. However, it has been noted that in the case of sensitive information, a telephone 
interview may foster individuals to feel comfortable and thus able to disclose sensitive information,30 
which we found to be the case with exploring the decision to opt out of a screening recommendation with 
our sample. In addition, participants were recruited within four months of their healthcare visit in which 
lung cancer screening was discussed, offered, and declined by the individual. Although the participants in 
our study did not have difficulty recounting their perspectives on reasons for declining to undergo lung 
cancer screening, there was a potential for recall bias.  Finally, participants were limited in 
racially/ethnically diverse representation potentially influencing the results. Future studies exploring the 
decision to opt out of lung cancer screening should include increased numbers of individuals from diverse 
backgrounds to provide a more robust picture of the opt out decision. A strength of the study was the 
ability to identify patients who were offered lung cancer screening by their provider. In many systems, it is 
difficult to evaluate individuals who opt out of a recommended service, as systematic documentation of 
the service being offered and declined are not captured. 
 
Conclusions 
Results from this study indicate that lung cancer screening awareness is low among screening-
eligible individuals. Screening offers a clinical platform in which shared decision-making is ideal. While 
providers are shifting to shared decision-making in other types of cancer screening,29 with lung, patients 
and providers are new to both the screening option and the shared decision-making process adding 
layers of complexity to the implementation of lung cancer screening. Therefore, it is critically important 
that both patients and providers are supported in methods that foster a shared decision-making process.  
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Table 1. Sample items from the semi-structured interview guide 
 
 Can you please describe how your provider told you about lung cancer screening? 
 How did s/he describe why lung cancer screening was important and what it involves? 
 When your healthcare provider recommended lung cancer screening to you, what was your 
response? 
o Why do you think you responded that way? 
 Was it difficult or easy for you to make your decision about lung cancer screening? 
o Can you please explain why? 
 Why do you think your provider recommended that you consider having lung cancer screening? 
Does anything worry you about lung cancer screening that you have not mentioned? 
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Table 2. Participant Sociodemographic Characteristics, Group Health Cooperative, Seattle, WA Nov 
2015-Jan 2016 
Variable N 
Gender  
  Male 7 
  Female 11 
  
Race  
  White 16 
  Black or Multiracial 2 
  
Smoking Status  
  Current Smoker 11 
  Former Smoker 7 
  
 Median (IQR) 
Age (years) 68 (55, 74) 
 
  
  
19 
19 
Table 3. Major Study Themes and Subthemes 
Objective Theme Subtheme Example Quote 
Patient-Provider 
Discussion About 
Lung Cancer 
Screening 
Being Qualified to Screen  “She [provider] handed me a paper 
and she said ‘read over this’…she 
didn’t really [describe it]. I got most 
of my information off the paper. I 
mean, she said I didn’t have to do it, 
but if I’d like to, they could set it up 
and I could go on and have it done.” 
 Discussion Followed by 
Provider Recommendation 
 “He recommended it because I had 
smoked a certain amount of time, a 
certain amount of cigarettes per day 
and…was eligible” 
    
Reasons for Opting 
Out of Lung Cancer 
Screening 
Knowledge Avoidance Fear of the Disease “so I didn’t choose to go do the test. 
If I did try to go do the test, I would 
be kind of scared, because I’ve been 
smoking since I was 12 and I really 
don’t – I mean, I can imagine what 
my lungs look like and what they 
might find.” 
  Fear of the Treatment “I think it’s fear of the unknown – if I 
know, well then there’s a scary 
response. You know you have to 
follow through and do more and 
more.” 
 Perceived Low Value Wasted Effort “It could show me if I had lung 
cancer and – what are they going to 
do?...screening for it doesn’t really 
make any difference because I’ll 
either come down with lung cancer 
or I won’t”. 
  Skepticism “What is it going to do? What is it 
going to prove? That I don’t have it 
right now. But in five years I could 
end up developing lung cancer from 
my past exposure”. 
 False Positive Worry  “I did schedule one and then after I 
read the print out and the office 
called me, I canceled it…the false 
positives were so high”. 
 Practical Barriers  “…I was still working at that time and 
I really didn’t have time to get over 
there during the week and so I 
haven’t had it done”. 
 Patient Misunderstanding  “once we got to the point where I 
realized it wasn’t going to be covered 
by my insurance, that was basically 
the end of it…if it had been less 
expensive, I would have done it”. 
 
 
